Clinical Trials
31 trialsCD4CAR for CD4+ Leukemia and Lymphoma
Indiana University
OPAL
AVM Biotechnology Inc
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Gyala Therapeutics
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Memorial Sloan Kettering Cancer Center
24CT015
Children's Hospital of Philadelphia
CASEY
Baylor College of Medicine
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
Beijing Boren Hospital
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Children's Oncology Group
Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma
Beijing Boren Hospital
BAH246
Essen Biotech
BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients
The First Affiliated Hospital of Soochow University
Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia
Hebei Senlang Biotechnology Inc., Ltd.
SportTherapy
University of Milano Bicocca
CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Alexion Pharmaceuticals, Inc.
Ruxolitinib for Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
CAR-T Cells in the Treatment of Malignant Hematological Tumors
Hebei Senlang Biotechnology Inc., Ltd.
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
Beijing Boren Hospital
Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies
iCell Gene Therapeutics
CD5CAR-T
iCell Gene Therapeutics
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
Nanfang Hospital, Southern Medical University
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
Nanfang Hospital, Southern Medical University
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
Virogen Biotechnology Inc.
Anti-Tac for Treatment of Leukemia
National Institutes of Health Clinical Center (CC)
Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia
BioCryst Pharmaceuticals
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac
National Institutes of Health Clinical Center (CC)
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
National Institutes of Health Clinical Center (CC)